Ulipristal acetate or Esmya for Uterine Fibroids

About Esmya to treat fibroids.

Ulipristal acetate (trade name EllaOne in the European Union, Ella in the U.S. for contraception, and Esmya for uterine fibroid) is a selective progesterone receptor modulator (SPRM) for emergency contraception within 120 hours (5 days) after an unprotected intercourse or contraceptive failure. It has been shown to prevent about 60% of expected pregnancies, and prevents more pregnancies than the emergency contraception scheme with levonorgestrel. Ulipristal acetate is available only by prescription in the U.S. and Europe, but without a prescription in India.

Ulipristal acetate is indicated for pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. The duration of treatment is limited to 3 months.

The treatment consists of one tablet of 5 mg to be taken orally once daily for up to 3 months. Treatment should be started during the first week of a menstrual cycle. There are no data available on treatment with a duration longer than 3 months or on repeat courses of treatment, therefore, treatment duration should not exceed 3 months. If a patient misses a dose, the patient should take ulipristal acetate as soon as possible. If the dose was missed by more than 12 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.